Vaccination With Detoxified Leukocidin AB Reduces Bacterial Load in a Staphylococcus Aureus Minipig Deep Surgical Wound Infection Model

Overview

Journal J Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2021 Apr 25

PMID 33895843

Citations 8

Authors

Jeffrey Fernandez

Holly Sanders

Jessica Henn

Jolaine M Wilson

Danielle Malone

Alessandra Buoninfante

Matthew Willms

Rita Chan

Ashley L DuMont

Craig McLahan

Kaitlyn Grubb

Anthony Romanello

Germie van den Dobbelsteen

Victor J Torres

Jan T Poolman

Affiliations

Soon will be listed here.

Abstract

Vaccines against Staphylococcus aureus have eluded researchers for >3 decades while the burden of staphylococcal diseases has increased. Early vaccine attempts mainly used rodents to characterize preclinical efficacy, and all subsequently failed in human clinical efficacy trials. More recently, leukocidin AB (LukAB) has gained interest as a vaccine antigen. We developed a minipig deep surgical wound infection model offering 3 independent efficacy readouts: bacterial load at the superficial and at the deep-seated surgical site, and dissemination of bacteria. Due to similarities with humans, minipigs are an attractive option to study novel vaccine candidates. With this model, we characterized the efficacy of a LukAB toxoid as vaccine candidate. Compared to control animals, a 3-log reduction of bacteria at the deep-seated surgical site was observed in LukAB-treated minipigs and dissemination of bacteria was dramatically reduced. Therefore, LukAB toxoids may be a useful addition to S. aureus vaccines and warrant further study.

Citing Articles

in Inflammation and Pain: Update on Pathologic Mechanisms.

Rasquel-Oliveira F, Ribeiro J, Martelossi-Cebinelli G, Costa F, Nakazato G, Casagrande R Pathogens. 2025; 14(2).

PMID: 40005560 PMC: 11858194. DOI: 10.3390/pathogens14020185.

Interleukin 10 drives Staphylococcus aureus imprinting and vaccine failure in murine models via antibody glycosylation.

Torres V J Clin Invest. 2024; 134(24).

PMID: 39680461 PMC: 11645138. DOI: 10.1172/JCI187055.

Mechanisms of host adaptation by bacterial pathogens.

Barber M, Fitzgerald J FEMS Microbiol Rev. 2024; 48(4).

PMID: 39003250 PMC: 11308195. DOI: 10.1093/femsre/fuae019.

senses human neutrophils via PerR to coordinate the expression of the toxin LukAB.

Savin A, Anderson E, Dyzenhaus S, Podkowik M, Shopsin B, Pironti A Infect Immun. 2024; 92(2):e0052623.

PMID: 38235972 PMC: 10863418. DOI: 10.1128/iai.00526-23.

Toward an effective Staphylococcus vaccine: why have candidates failed and what is the next step?.

Tsai C, Caldera J, Hajam I, Liu G Expert Rev Vaccines. 2023; 22(1):207-209.

PMID: 36765453 PMC: 9972957. DOI: 10.1080/14760584.2023.2179486.

References

Mohiti-Asli M, Risselada M, Jacob M, Pourdeyhimi B, Loboa E . Creation and Evaluation of New Porcine Model for Investigation of Treatments of Surgical Site Infection. Tissue Eng Part C Methods. 2017; 23(11):795-803. PMC: 5689126. DOI: 10.1089/ten.TEC.2017.0024. View

Lewis H, Molbak K, Reese C, Aarestrup F, Selchau M, Sorum M . Pigs as source of methicillin-resistant Staphylococcus aureus CC398 infections in humans, Denmark. Emerg Infect Dis. 2008; 14(9):1383-9. PMC: 2603104. DOI: 10.3201/eid1409.071576. View

Shinefield H, Black S, Fattom A, Horwith G, Rasgon S, Ordonez J . Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med. 2002; 346(7):491-6. DOI: 10.1056/NEJMoa011297. View

Tam K, Lacey K, Devlin J, Coffre M, Sommerfield A, Chan R . Targeting leukocidin-mediated immune evasion protects mice from Staphylococcus aureus bacteremia. J Exp Med. 2020; 217(9). PMC: 7478724. DOI: 10.1084/jem.20190541. View

de Haas C, Veldkamp K, Peschel A, Weerkamp F, van Wamel W, Heezius E . Chemotaxis inhibitory protein of Staphylococcus aureus, a bacterial antiinflammatory agent. J Exp Med. 2004; 199(5):687-95. PMC: 2213298. DOI: 10.1084/jem.20031636. View

Schulz D, Grumann D, Trube P, Pritchett-Corning K, Johnson S, Reppschlager K . Laboratory Mice Are Frequently Colonized with and Mount a Systemic Immune Response-Note of Caution for Infection Experiments. Front Cell Infect Microbiol. 2017; 7:152. PMC: 5411432. DOI: 10.3389/fcimb.2017.00152. View

Wu Y, Liu X, Akhgar A, Li J, Mok H, Sellman B . Prevalence of IgG and Neutralizing Antibodies against Staphylococcus aureus Alpha-Toxin in Healthy Human Subjects and Diverse Patient Populations. Infect Immun. 2017; 86(3). PMC: 5820940. DOI: 10.1128/IAI.00671-17. View

Golding G, Bryden L, Levett P, McDonald R, Wong A, Wylie J . Livestock-associated methicillin-resistant Staphylococcus aureus sequence type 398 in humans, Canada. Emerg Infect Dis. 2010; 16(4):587-94. PMC: 3321955. DOI: 10.3201/eid1604.091435. View

Dayan G, Mohamed N, Scully I, Cooper D, Begier E, Eiden J . Staphylococcus aureus: the current state of disease, pathophysiology and strategies for prevention. Expert Rev Vaccines. 2016; 15(11):1373-1392. DOI: 10.1080/14760584.2016.1179583. View

10.

Summerfield A, Meurens F, Ricklin M . The immunology of the porcine skin and its value as a model for human skin. Mol Immunol. 2014; 66(1):14-21. DOI: 10.1016/j.molimm.2014.10.023. View

11.

Thammavongsa V, Kim H, Missiakas D, Schneewind O . Staphylococcal manipulation of host immune responses. Nat Rev Microbiol. 2015; 13(9):529-43. PMC: 4625792. DOI: 10.1038/nrmicro3521. View

12.

Boguslawski K, McKeown A, Day C, Lacey K, Tam K, Vozhilla N . Exploiting species specificity to understand the tropism of a human-specific toxin. Sci Adv. 2020; 6(11):eaax7515. PMC: 7065885. DOI: 10.1126/sciadv.aax7515. View

13.

Bangerter P, Sidler X, Perreten V, Overesch G . Longitudinal study on the colonisation and transmission of methicillin-resistant Staphylococcus aureus in pig farms. Vet Microbiol. 2016; 183:125-34. DOI: 10.1016/j.vetmic.2015.12.007. View

14.

Johansen L, Frees D, Aalbaek B, Koch J, Iburg T, Nielsen O . A porcine model of acute, haematogenous, localized osteomyelitis due to Staphylococcus aureus: a pathomorphological study. APMIS. 2011; 119(2):111-8. PMC: 3040840. DOI: 10.1111/j.1600-0463.2010.02700.x. View

15.

Miller L, Fowler V, Shukla S, Rose W, Proctor R . Development of a vaccine against Staphylococcus aureus invasive infections: Evidence based on human immunity, genetics and bacterial evasion mechanisms. FEMS Microbiol Rev. 2019; 44(1):123-153. PMC: 7053580. DOI: 10.1093/femsre/fuz030. View

16.

Kolata J, Bode L, Holtfreter S, Steil L, Kusch H, Holtfreter B . Distinctive patterns in the human antibody response to Staphylococcus aureus bacteremia in carriers and non-carriers. Proteomics. 2011; 11(19):3914-27. DOI: 10.1002/pmic.201000760. View

17.

Gladysheva I, Turner R, Sazonova I, Liu L, Reed G . Coevolutionary patterns in plasminogen activation. Proc Natl Acad Sci U S A. 2003; 100(16):9168-72. PMC: 170890. DOI: 10.1073/pnas.1631716100. View

18.

Begier E, Seiden D, Patton M, Zito E, Severs J, Cooper D . SA4Ag, a 4-antigen Staphylococcus aureus vaccine, rapidly induces high levels of bacteria-killing antibodies. Vaccine. 2017; 35(8):1132-1139. DOI: 10.1016/j.vaccine.2017.01.024. View

19.

Scully I, Timofeyeva Y, Illenberger A, Lu P, Liberator P, Jansen K . Performance of a Four-Antigen Vaccine in Preclinical Models of Invasive Disease. Microorganisms. 2021; 9(1). PMC: 7830931. DOI: 10.3390/microorganisms9010177. View

20.

Forster R, Bode G, Ellegaard L, van der Laan J . The RETHINK project on minipigs in the toxicity testing of new medicines and chemicals: conclusions and recommendations. J Pharmacol Toxicol Methods. 2010; 62(3):236-42. DOI: 10.1016/j.vascn.2010.05.008. View